ADC Therapeutics (ADCT) Revenue (2023 - 2026)

ADC Therapeutics' (ADCT) quarterly Revenue came in at $20.0 million in Q1 2026, up 300.66% year-on-year from $5.0 million in Q1 2025, and up 27.19% quarter-over-quarter from $15.8 million in Q3 2025.

ADC Therapeutics (ADCT) Revenue (2023 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Revenue across 4 years of filings, most recently posting $20.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - 5.21 Mn
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 306.30 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 2.99 Bn
9 Abivax 91.71 Bn 91.71 Bn - -
10 ADC Therapeutics 167.24 Mn -63.76 Mn 7.33 Mn 20.03 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.03 Mn
Sep 30, 2025 15.75 Mn
Jun 30, 2025 18.84 Mn
Mar 31, 2025 5.00 Mn
Sep 30, 2024 18.02 Mn
Jun 30, 2024 17.03 Mn
Mar 31, 2024 18.05 Mn
Sep 30, 2023 14.49 Mn
Jun 30, 2023 19.28 Mn